A carregar...
Development of a palivizumab specialty pharmacy management program
Background: Palivizumab is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high risk pediatric patients. Due to the high cost, handling requirements, administration route, and importance of adherence, palivizumab is best managed...
Na minha lista:
| Publicado no: | J Drug Assess |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Taylor & Francis
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6764365/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21556660.2019.1658299 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|